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Abstract
Radioactive seed implant brachytherapy is a common radiotherapy
treatment method for prostate cancer. In current clinical practice, a seed
consists of a single isotope, such as 125I or 103Pd. A seed containing a
mixture of two isotopes has been proposed for prostate cancer treatment.
This study investigates a method for defining a prescription dose for new
seed compositions based on matching the biological equivalent dose
(BED) of a reference plan.
Ten prostate cancer cases previously treated using single isotope
seeds (5 using 125I seeds and 5 using 103Pd seeds) were selected for this
study. Verification of the method was done by calculating prescription
doses for 103Pd and 125I seeds. A prescription dose for a 50/50 hybrid seed
was calculated. Number and location of seeds remained invariant within
each case. The BED distributions for hybrid and single isotope seed plans
were generated and matched to the BED distribution generated off of the
optimized plans.
For the 125I isotopes, the dose necessary to cover 90% of the
prostate with a BED of 110 Gy is 145 Gy. For the same BED coverage,
the dose for 103Pd and 50/50 hybrid seed is 120 Gy and 137 Gy
respectively.

iv

A method is introduced for obtaining prescription doses for new
brachytherapy sources. The method was verified by obtaining doses for
125

I and 103Pd isotopes which match clinical prescription doses. The

method developed is robust enough to calculate prescription doses in any
region of interest, for any seed type, and for any isotope as long as the
BED coverage remains invariant with respect to the treatment plan.
Numerical calculations were performed to derive analytical
conversions of total dose to BED for 50/50, 75/25 and 25/75 hybrid seeds.
These analytical conversions are faster than the original numerical
methods employed allowing for real-time BED optimization for hybrid
seeds.
Varying seed distribution was seen not to influence the analytical
conversions. It was observed that when total dose remained invariant
while individual isotope contributions varied, the value of BED varied.
The BED variance was seen to be the smaller at larger BED values (~2%
at 100 Gy).
Using the conversions derived in this paper, BED based
optimization for hybrid seeds are now performable. However, these
conversions should only be used in high dose regions due to high
uncertainty in the low regime.

v

I. Introduction
History on Interstitial Brachytherapy
Brachytherapy is defined by the treatment of a disease through use of radioactive
sources placed within or on the body. Treatment of prostate cancer with brachytherapy
began in 1914 when Pasteau and Degrais inserted radium into the prostate through the
urethral catheter[1]. Interstitial implantation of radium needles was first used in 1917 by
Barringer[2]. By the mid 1970’s, modern interstitial brachytherapy for the treatment of
prostate cancer developed its formalism when in 1972 Whitmore et al. used 125I
radionuclide seeds. The delivery of the radioactive isotopes was done through needles
inserted retropubically. Depth coordinates for the needles were determined through
palpation of the prostate through the rectal cavity.
Since 1972, several improvements have been made to the implantation process
and radiation delivery of permanent seed implant brachytherapy[3]. First, brachytherapy
planning was optimized through use of patient images obtained either through transrectal
ultrasound probes or CT scans. Using the patient images sets as well as dose calculation
software (such as Variseed), better dose delivery by permanent seeds could be performed.
Another improvement to Whitmore’s technique was in streamlining the
implanting procedure. Palpating the prostate gave way to ultrasound guidance in
providing depth coordinates. Multi-channel grids, introduced in 1981 by Holm, et al.,
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were constructed to guide interstitial needles during implant procedures to insure proper
placement of the radioactive seeds in the lateral and posterior/anterior positions[4].
Prostate Cancer Treatment
Several criteria are used to determine which therapy modalities are available for
treatment of a patient’s prostate cancer. The Gleason grade is a pathological grading
system for measuring the degree of differentiation of prostate tumors[5]. A prostate
specific antigen (PSA) test is also performed to find the concentration of the PSA protein
within the patient’s blood. Finally, a digital rectal exam is also performed to check for
any abnormalities. Patients eligible for prostate brachytherapy usually have the following
criterion: a PSA level greater than 10, a Gleason grade of around 6, and minimal
abnormalities found after the digital rectal exam.

Figure [1] how a TRUS is set up within the patient. [Image credit:
http://www.strivewell.com/wiki/Image:TRUS.jpg ]
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For early stage prostate cancer, several treatment options are available: permanent
seed implant brachytherapy, external beam radiation therapy, prostectomy, or no
treatment. Each form of treatment has its own associated risks and side effects. Urinary
incontinence and impact on sexual function (impotence) may occur after prostatectomy[6].
Sexual dysfunction and irritative gastrointestinal and genitourinary side effects are
commonly reported following external radiation treatment for early stage prostate
cancer[7]. In permanent seed implant brachytherapy complications such as urinary
retention, urinary incontinence, and radiation proctitis may arise[8].
If the patient chooses to be treated with permanent seed implant brachytherapy
then after diagnosis the patient is brought in so that a transrectal ultrasound (TRUS)
probe (Figure [1]) can be used to image the patient’s prostate. These images are then
imported into a treatment planning software so that a treatment plan may be developed.

Figure [2] Placement of the coordinate plate. The grid is used to ensure that
brachytherapy seeds are correctly placed with regards to the LAT and AP coordinates.
[Image credit: http://en.wikipedia.org/wiki/File:Prostategrid.jpg ]
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Afterwards, the patient is brought back in for treatment. The TRUS is reinserted so depth
coordinates can be obtained as brachytherapy seeds are implanted. For the anteriorposterior (AP) and lateral (LAT) coordinates, a coordinate plate (Figure [2]) is placed
between the anus and scrotum.
Permanent implantation of sealed radioactive seeds within the target volume is a
definitive or supplementary therapy used for early stage prostate cancer[5, 9, 10] and has
been used in the past for other sites such as treatment for head and neck tumors[11-13].
(Figure [3] shows 125I seeds placed within a patient’s prostate.) The current technique of
prostate seed implants (PSI) uses single isotope seeds to deliver the prescribed dose to the
tumor[14, 15].

125

I and 103Pd are the most common radioactive isotopes used for PSI.

Based on their decay rates, 125I or 103Pd, has been prescribed to tumors considered
slow-growing and fast-growing as designated by their Gleason grade, respectively[16].
However, prescribing an isotope based on Gleason score has been criticized since no
advantages have been observed[15]. Nevertheless, differences in long-term complications
between the two isotopes has been reported: a grade III-IV complication rate with 103Pd
(0%) vs. 125I[17] (6%), increased risk of proctitis when 125I used vs. 103Pd[18], and radiation
prostatis[18]. Interest in use of new sources or a combination of sources for seed implants
for use in brachytherapy remains[19 - 21]. Since many isotope ratios are possible within
hybrid seeds, a method of obtaining a prescription dose for new and novel seeds is
warranted.

4

Figure [3] CT slice of the prostate after implantation of brachytherapy seeds. The white
dots in the center of the image are the locations of 125I seeds used to treat the prostate of
this patient. Pelvic bones can also be seen.
An effective treatment for prostate cancer is typically defined by chemical free
survival (ASTRO guidelines: no three consecutive rising PSA tests[22]). For early stage
prostate cancer treatments using brachytherapy as monotherapy, the accepted standard for
successful implants are that 90% of the prostate volume receives a dose of at least 145 Gy
or 120 Gy for 125I or 103Pd isotopes, respectively[23]. The effectiveness of the treatment is
thus predicted by the dose coverage of the prostate. Prescribed doses for PSI using
hybrid seeds or new isotopes have not been established. This paper will expand on the
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biological effective dose (BED) methods previously used to calculate prescription doses
for new brachytherapy sources[24].
From the dose distribution one can calculate a BED distribution. The BED is
used as a means to more accurately calculate the clinical expectation of different
treatment modalities[25, 26]. The conversion from dose distribution to BED distribution for
brachytherapy plans that use seeds of a single isotope has been previously reported[27].
However, for treatments using hybrid seeds, the calculation is complicated since no
analytical expression for effective treatment time (Teff) can be written. Teff is defined as
the time at which the cell killing rate equals the proliferation rate[27, 28] This is due to the
different dose rates from the isotopes contained within each seed. Therefore, a system of
equations is needed to solve the set of transcendental functions when calculating the BED
and Teff. This paper introduces a numerical method, to calculate BED distributions for
PSI which then can be used to calculate prescription dose for new types of sources.
Derivation of BED
The best model for a cell survival curve is the linear quadratic model[29]. This
model in a very general way models the effectiveness of single and double strand DNA
breaks. Taking into account the effect that dose has, the model characterizes the single
and double strand breaks. Single strand breaks are proportional to dose, D, while double
strand breaks are proportional to dose squared (D2).
The relationship between cell survival and dose is given by:

S = e−αD − βD

2

(1)

Here, S is the cell survival fraction for a given dose, D. The parameters α and β describe
the log of cell death per dose and dose squared, respectively[29]. Specifically, α describes
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the sensitivity of a cell line to single strand DNA breaks while β describes the sensitivity
to double strand breaks. The factors of α and β are determined by cell lines and have
been characterized by the early- and late- responding tissues[30]. Table [1] shows a listing
of α/β ratios for various cell lines.
Table [1] α/β values for various cell types. Note that cancer cells typically have higher
α/β ratios indicating early responding tissues.

Cell Type

α/β (Gy)

Heart

2.0[31]

Eye lens

1.2[31]

Liver

1.5[31]

Brain

2.1[31]

Prostate Cancer

3.1[27]

Rectal Cancer

5.06[32]

Lung Cancer

10[33]

The parameters α and β establish a way of denoting the biological effect (E) that
radiation has on cells.
E = − log(S )

(2)

E = αD + β D 2

(3)

Equation [3] is the biological effect for a single acute dose, D. However, for n separated
fractionations of dose, d, (where nd = D) the biological effect is:
E = n (αd + nβ d 2 )

(4)

βnd
)
α

(5)

E = αnd (1 +
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Here the quantity, (1 +

β nd
) , is called the relative effectiveness (RE). Dividing Equation
α

[5] by α yields a quantity known as biologically effective dose (BED). This quantity of
BED is used to compare different fractionation deliveries[29].
BED =

E

= (nd )(1 +

α

β nd
)
α

(6)

The BED has been proposed as a way to establish the effectiveness of isotope
selection[17]. The conversion from total dose to BED for brachytherapy plans that use
seeds of a single isotope has been established[27]. In those plans, local dose rates as a
function of time follow the decay formula of the corresponding isotope, making the
conversion simple. However, for treatment plans using hybrid seeds, the calculation is
complicated and no simple formula can be derived from the BED equations. This work
introduces a method, using a numerical approach, to calculate the BED from dose
distributions arising from these hybrid seeds.
Since the effectiveness of a treatment is denoted by prostate dose coverage, one
can calculate an effective BED distribution from an effective dose distribution. Once this
is done, BED distributions of new sources can be matched to those BED distributions
calculated from effective dose distributions. After the BED distribution of the new
isotope is matched to the BED distribution of an effective plan, a prescription dose can be
calculated for the new source. This method is described in detail in subsequent chapters.
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II. Model & Method of Calculation
Treatment plans
A total of ten prostate cancer cases previously treated using single isotopes, five
125

I and five 103Pd, were selected for this study. Since TG-43 bases the prescription dose

on post implant CTs, these image sets were used to calculate dose distributions from seed
locations. The CT image sets also provided a means of obtaining the contours of the
prostate, rectum and bladder. Because the post implant CT images were used for this
study, the dose distribution was calculated for this seed arrangement and then the seed
activity was adjusted to ensure that 90% of the prostate is covered by the prescription
dose (145 Gy for 125I and 120 Gy for 103Pd).
These image sets also provided seed distribution information. After the BED and
dose distributions were calculated for the treatment isotope, the treatment isotopes were
removed and replaced with a new isotope or isotope mixture (using the same seed
distribution). The method used in this paper requires the seed distribution to be the same
between the treatment isotope and plans generated from the treatment isotope. Therefore,
work done in this paper did not investigate optimizing the generated plans through
varying seed number and location.
The hybrid seeds used in this study are a 125I and 103Pd combination. The total
dose in water at 1 cm away from the seed has equal dose contributions from both
isotopes. Figure [4] illustrates this concept. This is why the hybrid seed is considered a
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50/50 mixture. Since the hybrid seed uses a 50/50 composition, it should be expected
that the dose to generate the same BED for the hybrid seeds is between the doses of the
two single isotopes.

103

103

Pd

1 cm
Pd

r

125

I

103

Pd

103
103

PdPd

Figure [4] schematic of the Advantage Hybrid PdI source. The 4.5 mm long seed
is comprised of both 103Pd and `125I. The seed is designed so that at r equal to 1 cm, the
dose contributions from the 103Pd and 125I are equivalent.
Since the prescription dose for 103Pd and 125I are known, these isotopes can be
used as a verification of the method introduced in this paper. If the reference plans used
the 125I isotope, a generated plan will use the 103Pd isotope. The BED distributions
between the two plans are then matched within the organ of interest and a prescription
dose can be back calculated from the generated plan that used 103Pd. The verification is
done vice versa for reference plans using 103Pd and whose generated plan uses 125I.
It is assumed that BED coverage for the prostate within the reference plans create
an effective treatment. Therefore, the same BED coverage is needed when generating
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plans for 103Pd and the hybrid seeds. Only the activities of the 103Pd and hybrid seeds
were allowed to change since this is what influences dose distributions and subsequently
BED distribution.
BED calculation
A computer program was developed to calculate the BED resulting from hybrid
and single isotope seeds. The BED equations for a hybrid point source and single isotope
point source take the form of Equations [7][19] and [8][27], respectively. (The source code
is contained within Appendix [A].)
N

BED (t , Doi' , Doj' ) = ∑
i

−

Doi'

λi

β
α

(1 − e −λi t )+ 2( )(∑∑
i

j

Doi' Doj'

1
1
−( λ + λ ) t
−( µ + λ j )t
(1 − e i j ) −
(1 − e
)})
µ − λi λi + λ j
µ + λj
{

0.693Teff

αT p

[7]
'
0

BED (t , D ) =

D0'

λ

2

(1 − e

− λt

0.693Teff
1
1
β D0'
(1 − e − ( µ + λ )t )} −
)+ 2( )
{ (1 − e − 2λt ) −
α µ − λ 2λ
µ+λ
αT p
[8]

Here N is the number of different types of seeds, λi is the respective decay constant, t is
time, and µ is the damage recovery constant (a biological parameter). The parameters, α
and β, are radiobiological constants associated with dose and dose squared damage; Tp is
the tumor potential doubling time (in this study its value is roughly 40 days)[19]. The
parameter D0' is the initial dose rate. The factor Teff is the effective treatment time,
defined as the time at which the cell killing rate equals the proliferation rate[27, 28].
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Figure [5] an axial CT slice with a dose distribution overlain. Colors closer to the red
spectrum indicate a higher dose relative to the blue colors. The high dose regions
coincide with the 125I seeds.
The first step in the process was to calculate the BED for the previously planned
treatment plans which use a single isotope, 125I. The treatment plans only had dose
distribution and organ contour information. (Figure [5] shows a CT slice with the
corresponding 125I dose distribution overlain.) Each voxel within the dose distribution
contains the dose for that voxel. Calculations will be performed on a voxel by voxel
basis. Typical dose distributions contain 512 by 512 voxels per slice. There are
approximately 24 slices per dose distribution image set.
An inspection of Equation [8] reveals two unknowns, BED and t. Therefore, a
system of two equations is necessary in order to calculate the BED. Using the definition
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of Teff, evaluating time derivative of the single isotope BED equation when t equals Teff
will yield a zero result[27]: Mathematically, this is:
∂BED
|t =Teff = 0
∂t
In addition to the system of equations, Equations [8 & 9], and the dose

[9]

distribution, biological information is needed for each voxel. This information is
provided by organ contours that are generated when the treatment plan for 125I is
generated. As in the dose distributions, each voxel within the contour maps contain the
information as to what kind of cell that voxel is. (In this study it is bladder, prostate,
rectum, or other normal tissue. Table [2] provides the biological information used in this
study.) With this information, a BED distribution, analogous to a dose distribution, can
be generated for the single isotope 125I seed. Subsequently, the BED coverage for the
prostate is now established per case for all seed modalities since it is a requirement of this
study that the BED coverage be the same for all seed modalities.
Table [2] Biological parameters used in BED calculation. An α/β of 3 was assumed for
late responding normal tissues, since this tissue is comparable to prostate cancer[37-39].
Tissue
α (Gy-1)
Prostate Cancer
.15[27]
Rectum
.0484[30]
Bladder
.0774[30]
Other normal Tissue
.2[37]

β (Gy-2)
0.048[27]
0.012[30]
.02[30]
0.067[36]

µ(days)
.0125[27]
.0164[34]
.0313[35]
.0488[36]

The next step is to generate the dose distributions for 103Pd and the hybrid seed
modalities. For 103Pd, the number of unknowns will be two just as in the 125I seed
modality since it is a single isotope seed. To start, a voxel is selected from the 125I BED
distribution so that the calculation to obtain the initial dose rate and t can be performed
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Figure [6] a zoomed in slice of a three dimensional 125I BED distribution. The large red
structure are contours for the prostate and rectum (from top to bottom respectively). The
red colors within the prostate contours illustrate high BED regions. Lower BED values
are illustrated by colors closer to the purple. The yellow arrow indicates the area where a
voxel could be selected.
Using the isotope parameters for 103Pd, the system of Equations [8 & 9] will be used
again to calculate the initial dose rate for the selected voxel. The voxel selected was
required to lie on the prostate periphery where there was not a high dose gradient;
however, the dose value within of the voxel is to be that of the prescribed dose for 125I.
Figure [6] above illustrates a selection voxel.
Having this information ( D0' and Teff) and coupling it with the seed number and
location obtained from the 125I treatment plan, one can calculate the air kerma strength
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needed to generate this initial dose rate. It is well established that for a set of radioactive
seeds distributed three dimensionally, that the air kerma strength goes as[20, 23]:

D0'
S= #
g (r ) i Φ an ( r ) i
Λ∑
ri 2
i

[10]

S is the air kerma strength. The following parameters are seed construction and isotope
dependent: Λ is the dose rate constant, g(r)i is the radial dose function, and Φan(r)i is the
anisotropy function. The radial dose function, g(r), accounts for dose fall due to
scattering and attenuation. The anisotropy function, Φan(r), takes into account the
variation in dose as a function of polar angle. The seed construction parameters are given
by the manufacturer and listed in Table [3].
Table [3] Construction parameters used in BED calculation. g(r) and Φan(r) were linearly
interpolated from data given[20]. It should be noted that the activities listed give a dose of
144 Gy 1cm away from the seed (when measured in water); the ratio of these activities
must remain the same (the values themselves can change).
Isotope
125
I
103
Pd

S (U)
0.22
1.42

Λ (cGy/h/U)
0.95
0.69

g(r) (cm)
1.111 - 0.139r
1.135 – 0.186r

Φan(r) (cm)
0.212 + 0.075r
0.267 + 0.012r

λ (days)
59.4
17

In calculating the 103Pd BED distribution, another stipulation needs to be made:
the air kerma strength for each seed is to be the same. With the activity of each seed
known, Equation [10] can be rearranged and solved for initial dose rate distribution.
With the initial dose rate distribution known the total dose distribution can be calculated
using:

D = 1.44T1 / 2 D0'

15

[11]

Here T1/2 is the half life for the isotope.
To obtain the BED distribution, the same process is implemented as was used for
125

I. However, it needs to be stated that the BED coverage within the prostate for 103Pd

be the same as for 125I. This is done by manually adjusting the air kerma strength and
recalculating to obtain a similar BED coverage that matches the BED coverage calculated
from the treatment plan.
In generating BED distributions for the hybrid seed modality, extra steps are
required. Examining Equation [7] reveals three unknowns: two initial dose rates and
time. Therefore, a third equation will be needed to solve for all three variables. Since
Equation [10] is constructed from parameters given by the manufacturer, an initial dose
rate ratio, Equation [12], can be constructed:
#
'
01
'
02

D
D

S1 Λ 1 ∑
=

i

#

S2Λ 2 ∑

g (r ) i Φ an (r ) i
ri 2
g (r ) j Φ an (r ) j

[12]

r j2
For the hybrid seed, the air kerma strengths values within Equation [12] will be
j

given by the manufacturer of the Advantage HybridTM seed (Table 3). The same process
is followed as performed for 103Pd but using three equation and solving for three
unknowns. When adjusting the air kerma strengths of the hybrid seed, the ratio of the air
kerma strengths must match the air kerma strength ratio given by the manufacturer.
Figure [7] gives a summarized view of the calculation process for this study.
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A dose map is generated using
prescription specifications
provided by the doctor.

Using Equations [8 & 9], a BED map is
generated. Contours are shown to note that
different pixels have different α, β, and µ
values depending on the cell type.

Selected point on the edge of the prostate
of the 125I BED map. Using this BED
value and Equations [8 & 9], Teff and
D&0 Pd are calculated for the 103Pd isotope.
For the hybrid seed, Equations [7, 9, &
10] are used to find Teff, D&0 Pd, and D&0 I.

With D&0i known, Equation [11] is
used to find the activity. The
activity is assumed to be the same
for each seed. Equation [12] is
then used to generate dose maps for
the respective isotope or mixture.

Equations [8 & 9] or Equations
[7, 9, & 10], depending on the
seed, are then applied to their
respective dose maps to calculate
the 103Pd or hybrid BED maps.

Figure [7] a calculation flow chart from the 125I dose map to the 103Pd or hybrid BED maps.
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III. Hybrid Seeds vs. Single Isotope Seeds
Patient Parameters
All ten patients selected were diagnosed and treated for early stage prostate
cancer. They were treated with either 125I or 103Pd brachytherapy with a prescription dose
of 145 Gy or 120 Gy, respectively. Table [4A] shows that the prostate volumes treated
using 125I isotopes; Table [4B] shows the prostate volumes treated using 103Pd isotopes.
Tables [5A-B] show the activity selection for the 125I and 103Pd isotopes, respectively.
Table[4A] Prostate volumes for the patients for patients who had 125I seeds
Patient
1
2
3
4
5

Prostate Volume (cc)
40.4
42.4
31.4
34.2
26.1

Table[4B] Prostate volumes for the patients for patients who had 101Pd seeds
Patient
6
7
8
9
10

Prostate Volume (cc)
31.08
35.83
23.10
23.29
23.62
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Table[5A] Activities used for the 125I seeds implanted
Patient
1
2
3
4
5

125

I seed activity mCi
0.635
0.635
0.635
0.610
0.635

Table[5B] Activities used for the 103Pd seeds implanted
Patient
6
7
8
9
10

103

Pd seed activity mCi
1.8
1.8
1.6
1.6
1.9

Results
When solving the system of equations for the 125I isotope with a prescription dose
of 145 Gy, the resulting BED is 110 Gy. This BED value was used to cover the same
volume within the prostate for the 103Pd isotope and hybrid seed plans. Tables [6A-B]
show the dose needed to achieve this coverage for each case. The average dose for the
125

I isotope, hybrid seed, and 103Pd isotope is 145 Gy, 136 Gy (+ 2 Gy), and 120 Gy,

respectively. The results in Table [6A-B] confirm the expectation that the dose for the
50/50 composition, when the BED coverage is the same in each seed, be between that of
125

I and 103Pd. The calculation of 120 Gy for the 103Pd isotope and 145 Gy for 125I isotope

coincides with the traditional prescription values, thus verifying the method used in this
study.
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Table[6A] Dose (Gy) to cover 90% of the prostate when BED coverage is the same (125I
treatment isotope).
Patient
1
2
3
4
5
Average
σ

125

103

I
145
145
145
145
145
145
0

Pd
120
120
120
120
120
120
0

50/50
137
133
138
137
137
136
2

Table[6B] Dose (Gy) to cover 90% of the prostate when BED coverage is the same
(103Pd treatment isotope).
Patient

6
7
8
9
10
Average
σ

103

Pd

120
120
120
120
120
120
0

125

I

50/50

145
145
146
145
145
145
0

136
139
137
136
136
137
1

As an example, the dose-volume histogram (DVH) for one case is illustrated in
Figure [8A]. The DVH curve for the hybrid seed initially mimics the 125I DVH curve;
however, at higher dose, the hybrid DVH curve behaves like the 103Pd DVH curve.
Examination of the slopes within Figure [8A] correlates the result obtained in Table [6A].
The corresponding comparison for BED-volume histogram (BED-DVH) for the
same case is presented in Figure [8B]. The BED-DVH curves for the different seed
modalities for this case are almost the same, indicating closer BED homogeneity within
the prostate between the seed modalities as compared with the dose homogeneity in the
DVH comparison.
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Figures [9A-B] are the same types of graphs as Figures [8A-B]; however, the
reference plans used 103Pd isotopes unlike the 125I reference plan isotopes used in Figures
[8A-B].

Prostate DVH for 125I, Hybrid, & 103Pd
1.0
125

I

0.8
103

DVH

Pd

0.6

Hybrid

0.4

0.2

A
0.0

0

100

200

300

400

500

Gy

Prostate BEDVH for 125I, Hybrid, & 103Pd
1.0
125I

0.8

BEDVH

103Pd

0.6

Hybrid

0.4

0.2

B
0.0

0

100

200

300

400

500

Gy
Figure [8] (A) Prostate DVH for 125I (treatment isotope), Hybrid, and 103Pd seeds. The
prescribed BED covers 90% of prostate in each case. (B) Prostate BEDDVH for 125I
(treatment isotope), Hybrid, and 103Pd seeds .
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Prostate DVH for 125I, Hybrid, & 103Pd
1.0

BEDVH

0.8

0.6
125I

0.4
103

Pd

0.2

0.0

Hybrid

0

A
50

100

150

200

Gy

Prostate BEDVH for 125I, Hybrid, & 103Pd
1.0

BEDVH

0.8

0.6
125I

0.4
103

Pd

0.2

0.0

Hybrid

0

B
50

100

150

200

Gy

Figure [9] (A) Prostate DVH for 125I, Hybrid, and 103Pd (treatment isotope) seeds. The
prescribed BED covers 90% of prostate in each case. (B) Prostate BEDDVH for 125I,
Hybrid, and 103Pd seeds (treatment isotope).
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IV. Discussion and Conclusions
Discussion
Historically, recommended prescription doses for radiation therapy have been
determined by treatment efficacy and normal tissue toxicity(5, 40, 41). The method
introduced in this paper provides a way of estimating a prescription dose based on the
efficacy of isotopes already clinically implemented.
In a previous study done by Chen and Nath(19), a generalized BED equation for
multi-isotope source distributions was derived. They applied the equation to calculate
the BED distribution for a mixture of 125I and 103Pd seeds. They found radiobiological
“cold” spots arose depending on the prescription dose used. Since the plans developed
use a mixture of different seeds and seed placement, the required prescription dose to
achieve the same radiobiological effect will be unique to each plan. The method outlined
in this paper provides a way of calculating a prescription dose for a mixed seed
distribution.
In a recent study by Todor et al. investigated using dual-isotope permanent seed
implants to create focal based brachytherapy treatments in prostate cancer[21]. A focal
based brachytherapy treatment plan involves escalating the BED to the foci of the disease
while reducing the prescription dose to the less involved prostate. The focal based
brachytherapy treatment discussed by this work involved the use of different
brachytherapy sources. For the general coverage of the prostate, the authors developed
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plans using either 125I or 103Pd isotope. For boost to the foci of the disease, an isotope
with a shorter half-life was used (such as 103Pd or 131Cs). Using this approach, they
calculated dose distributions for plans that used 125I, 103Pd, or 131Cs as sole single isotope
plans or in combination to generate a higher BED to the suspected foci. For both types of
calculations, conventional prescription doses were used for the general prostate coverage;
however, for plans that included a foci boost using a second isotope, the prostate volume
covered by the prescription dose was smaller. The plans were then compared using the
equivalent uniform BED (EUBED). The method developed by Todor et al. provides a
way of designing focused based brachytherapy plans that use a combination of different
brachytherapy seeds. Since their method delivers focused based treatment, each
treatment plan developed will have its own prescription dose.
The work provided by Todor, et al. used an analytical expression for Teff. When
using this approach of a single isotope for general coverage and a different isotope for the
suspected foci of disease, the distribution of sources allows one to approximate the Teff
locally. So the effect of a long lived isotope on the Teff for a short lived isotope was
ignored as a first approximation. When looking at a hybrid source or a more general
mixture of sources, this approximation may not be appropriate.
The two studies mentioned above investigate the consequences of using a
distribution of mixed brachytherapy sources. Calculating a prescription dose for plans
that use a distribution of mixed sources would have to be done on a case by case basis
since each mixed seed distribution results in a specific BED distribution. The method
outlined in this paper can be used to calculate the prescription dose necessary for these
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mixed seed plans; however, stating a general prescription dose (as one would do when
using one type of seed) is not recommended.
The method developed in this paper provides a general way of studying various
seed configurations. This study limited itself to three seed configurations: pure 125I, pure
103

Pd, and a 50/50 combination of 125I and 103Pd. However, other seed configurations

could easily be studied such as a 75/25 mixture, a composite seed distribution (where
pure seeds of 125I are interspersed with pure 103Pd seeds), as well as other seed modalities.
It is important to notice that the above prescription doses are based on α, β, and µ
values listed in Table [2]. Different α and β values have been reported by different
groups[39, 42, 43]. If different α, β, and µ values are used, the prescription dose for each seed
type will change accordingly. A different isotope ratio other than the 50/50 in the hybrid
seed would require a different prescription dose to achieve the same BED coverage.
Since this method is essentially organ invariant, this study could also be applied to
interstitial brachytherapy not intended for the prostate (such as in breast). The basic
information needed to perform this study are: seed construction parameters, number and
location of seeds, isotope parameters, and finally the biological information which is
obtained via the organ contours.
Conclusions
The method introduced uses information taken from post-implant CT images.
Since analysis of treatment efficacy can only take place after permanent seed
implantation, prescription doses can only be determined from these image sets.
However, because a prescription BED can be calculated for these image sets, prescription
doses for new isotopes can be determined by setting the BED coverage of the new
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isotope equal to the BED coverage calculated for the treatment isotope. This process was
verified twice when clinical prescription doses were calculated for the 103Pd and 125I
isotopes.
By matching BED coverage within the prostate, a way of obtaining a prescription
dose for new and novel sources for use in brachytherapy is demonstrated within this
paper. The method introduced is site and isotope invariant and only requires few
knowns: the treatment dose distribution, isotope information, seed construction
parameters, and biological information for the areas of interest. The method was then
applied to a newly proposed source: the 50/50 Advantage Hybrid for which the
prescription dose calculated was 136 Gy.
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V. Dosimetric Optimization for Hybrid Seed Brachytherapy
Introduction
The linear-quadratic model is currently the most used model that quantitatively
describes the survivability of a cell line for a given amount of radiation. Deriving from
the linear quadratic model, the biological effective dose (BED) describes the biological
effects of radiation[28, 29]. Since BED provides a way of including radiobiological
parameters, quantitative expectations can be obtained[44]. It has been suggested that BED
be used as a guide in clinical decision making[26, 44-47]. This requires the calculation of
BED from dose. Several papers have addressed the conversion of dose to BED for
fractionated external beam radiation therapy[26, 28, 29, 45], in brachytherapy[19, 27, 46], and for
composite modalities (external beam with brachytherapy)[36].
With modern technologies, multiple radiotherapy treatment modalities are
available to treat cancer. Even to treat the same lesion, multiple modalities may be
involved. An example of such radiotherapy is prostate cancer being treated with external
beam radiotherapy initially followed by seed implant brachytherapy as a boost treatment.
Because of the dose rate differences between various treatment modalities, the radiation
dose cannot be directly used to compare treatment outcomes of the various modalities.
For a lesion treated with multiple modalities, the total dose from the treatments is not
meaningful. To analyze these cases, BED needs to be used.
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BED based optimization is thus necessary when multiple treatment modalities are
involved. Currently, dose based optimization is common but BED based optimization is
not available in commercial treatment planning systems. To make BED base
optimization possible, a fast dose-BED conversion must be established. Since the
relation between dose and BED is not linear, dose characteristics of each seed type do not
necessary reflect the characteristics of BED. It was therefore necessary to set a standard
by which various seeds can be compared (BED). Through this, one can set up a
correlation between BED and dose.
Depending on the dose delivery mechanism, calculation of BED from radiation
dose is relatively straight forward. For fractionated external beam radiation therapy,
BED follows[47]:
BED = nd (1 +

ln 2(T − Tk )
d
)−
,
α /β
α ⋅ Tp

(13)

where, n is the number of fractions, d is the dose per fraction, T is the overall treatment
time, Tp is the cell number doubling time, Tk is time at which repopulation starts after
treatment has started. The terms α and β are standard radiobiological parameters that
describe radiation effects on cells.
For brachytherapy using single isotope seeds, the BED equation can be
approximated for clinical applications as[46]:

BED = D{1 + 2( D0' * λ )( β / α ) * (

κ
µ −λ

)} −

.693 * T
,
α ⋅ Tp

(14)

where

κ =(

1

1− e

− λTeff

−2 λT

− λT

1 − e eff
1 − (e eff * e
){(
) −[
2*λ
µ +λ
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− µTeff

)

]}

(15)

Teff =

1

λ

* ln[(1.44 * D0' ) * (α * T p )] .

(16)

Here, D is total dose, D0' is the initial dose rate, λ is the isotope decay constant, and Teff is
the effective treatment time. Using the equations above, conversion from total dose to
BED is straightforward.
Due to the mixture of dose rates, the calculation of BED becomes more
complicated for multi-isotope seeds. The mixture of dose rate prevents an analytic
expression of Teff and so a system of equations is needed for calculating BED. The
equations necessary for calculating the BED for the multi-isotope seeds are the BED
equation (Equation [7])[19] and the time derivative of the BED equation (Equation [9])[27].
For hybrid brachytherapy the computation of BED is difficult because of the
mixture of dose rates. Numerical computation of BED is possible; however, this process
is time consuming[48]. Without an efficient way of computing BED in hybrid
brachytherapy, dosimetric analysis of treatment plans becomes difficult. Thus, a fast
dose - BED conversion method is desirable. The purpose of this paper is to introduce a
fast dose – BED conversion so that possible BED based treatment plan optimization
using hybrid brachytherapy seeds is feasible.
Materials & Methods:

A numerical approach was established to calculate BED distributions from initial
dose rate distributions for hybrid seed implant brachytherapy. The 50/50 hybrid seed
contains a mixture of 103Pd and 125I that contribute equal amounts of dose at 1 cm away
from the seed[20]. Other hybrid ratios are possible and their name denotes the dose
contributions by each isotope (i.e. a 75/25 hybrid seed has 75% dose contribution from
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125

I and 25% from 103Pd). Dose distributions and initial dose rate distributions were

calculated using Equation [10 & 11][23].
In Equation [8] shows a unique correspondence between total dose and BED for a
single isotope source. Therefore, a dose-BED conversion table can be easily established
for single isotope seeds. However, for hybrid seeds it is possible that a total dose could
have multiple corollary BED values due to the dependence of BED on the initial dose
rates (This idea is illustrated in Figure [10]). Equation [10] shows the relation of initial
dose rate with distance. Since each isotope has a different geometric function, the ratio
of dose contributions from the isotopes will vary with distance. Therefore, to generate a
dose-BED conversion table for hybrid seeds, the relation of individual dose contributions
to BED, (while maintaining a constant total dose) needs to be established.

Figure [10] illustrates an isodose line for 2 hybrid seeds. Total dose remains the same

along the isodose line; however, individual isotope dose contributions will vary. Areas in
blue will have relatively equal isotope dose contributions from each seed. Areas in red
will have isotope dose contributions that differ from each seed. The arrows are to
indicate relative distances of the seeds to points on the isodose line.
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To investigate how much effect varying individual dose contributions while total
dose remains invariant has on the BED value, calculations were performed to see if the
number of hybrid sources influenced the relation of total dose to BED. Three
dimensional dose distributions were calculated for 2, 5, 10, and 49 planar seed
distribution. From these dose distributions, the BED distributions were calculated.
Finally, the total dose values were coupled with their corresponding BED values and a
graph of dose component versus BED was constructed.
If the variance in BED values for a certain total dose was found to be large, then a
dose-BED conversion table would not be useful clinically since there would be multiple
BED values for one total dose. However, if the variance in the BED value is found to be
small with respect to BED value, then practical applications of a dose-BED conversion
table can be considered.
Finally a seed distribution and organ contours were taken from a post-implant CT
image set in accordance with the TG-43 protocol. This image set came from a patient
previously treated with single isotope (125I) permanent seed implant brachytherapy. The
image set also contained the information about the activity of the seeds. The sources
used in this plan were replaced with hybrid seeds. A dose distribution was then
calculated for this hybrid seed set; the BED distribution was then calculated.
In addition to calculating dose-BED graphs for a 50/50 hybrid seed, other ratios
were investigated as well. Graphs were generated for a 75/25 and 25/75 hybrid seeds.
(The ratio is presented as 125I/103Pd). Activities of the seeds were adjusted to reflect the
isotope ratios investigated. These activities are given in Table [7]. Note that Λi, g(r)i and
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Φan(r)i remained the same for these ratios. Once the activities were adjusted, dose

distributions followed by BED distributions could be calculated.
Table [7] air kerma strength of isotopes within the hybrid seed that generate the

appropriate dose contribution ratios to a total dose of 144 Gy 1 cm from the seed in
water.
Isotope
125
103

I
Pd

50/50
(U)
0.22
1.42

75/25
(U)
0.33
0.71

25/75
(U)
0.11
2.13

Because BED can vary depending on the tissue medium, dose vs. BED figures
were generated for multiple tissue types: normal tissue, prostate, bladder wall, and
rectum. Values for the α, β and µ used in this study are given in Table [2]. For each new
set of biological parameters, the numerical method had to be applied.
For each total dose vs. BED graph, a line of best fit was determined using Excel’s
polynomial fit. Since these equations are analytic, fast calculations can be performed
with them. In optimization implementation these derived equations should be used.
Results:

Because a hybrid source contains multiple isotopes, the dependency of individual
isotope dose contributions to BED needs to be investigated. The BED, total dose, and
individual dose components were calculated for a 49 seed distribution within a prostate
medium. The individual dose contributions for a given total dose leads to a BED
variance seen in Figure [11].
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Total Dose vs. Isotope Dose Components or BED (49 seeds prostate)
80
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BED

BED or dose (Gy)

70

I-125 dose

65

Pd-103 dose

60
55
50
45
40
100

101

102

103
total dose (Gy)

104

105

106

Figure [11] the individual isotope contributions to total dose vs. BED relation for 49

seeds. This graph was calculated for prostate.
Figures [11] show that for a specific total dose value, multiple individual dose
contribution combinations from each isotope exist. This causes a variance in BED value
for a specific total dose. However, the variance in BED as compared to the variance in
isotope dose contributions is small.
Next, an investigation as to whether the number of seeds influences the BED
value was investigated. Figure [12] shows the total dose to BED conversions for a larger
range of values. The data points for 2, 5, 10, and 49 seeds are seen to overlap suggesting
that number of seeds does not influence the relation of total dose to BED.
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Total Dose vs. BED for multiple number of sources
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200
dose (Gy)

250

300

350

Figure [12] total dose vs. BED for differing number of seeds and distributions. This

graph was calculated for prostate.
Since the BED variance was seen to be small, generating total dose vs. BED
graphs can be done. Figure [13] shows the total dose vs. BED graphs for rectal tissue for
hybrid seed ratios of: 50/50, 75/25 and 25/75. From these graphs, polynomial equations
can be fitted. These equations allow for a quick conversion of total dose to BED. For
other tissues (prostate, bladder and normal tissue), the numerical technique was applied in
order to obtain the total dose vs. BED data set. A polynomial equation was generated to
fit each data set. For these tissues types, the three isotope ratios were investigated.
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Total Dose vs. BED for hybrid seeds (rectum)
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Figure [13] shows the total dose vs. BED calculated for the rectum for hybrid seeds of

ratio: 25/75, 50/50 and 75/25.
A polynomial equation to the fourth power was generated by Excel for the
following scenarios: rectal, prostate, bladder and normal tissues for hybrid seeds of ratio:
50/50, 25/75 and 75/25. Coefficients for these equations as well as the R2 value are listed
in Table [8]. The general form of the polynomial fit is given in Equation [17].

BED ( D ) = AD

4

+ BD
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3

+ CD

2

+ ED + F

[17]

Table [8] Coefficients for equations of fit for BED vs. dose data sets. NT = Normal

Tissue
Coefficients

Hybrid
Seed Type

Organ

A

B

C

E

F

R2

50/50

Prostate

1.074×10-8

-8.877×10-6

2.802×10-3

0.605

-4.765

0.999

50/50

Rectum

1.670×10-8

-1.372×10-5

4.489×10-3

0.246

-7.792

0.999

50/50

Bladder

3.960×10-7

-1.216×10-4

1.520×10-2

-0.038

-2.192

0.999

50/50

NT

9.729×10-9

-8.023×10-6

2.968×10-3

0.661

-4.923

0.999

75/25

Prostate

2.000×10-8

-1.000×10-5

0.004

0.465

-4.160

0.999

75/25

Rectum

2.000×10-8

-2.000×10-5

0.006

0.015

-1.979

0.999

75/25

Bladder

1.917×10-8

-1.643×10-5

5.360×10-3

0.205

-3.784

0.999

75/25

NT

1.171×10-8

-9.750×10-6

3.325×10-3

0.594

-5.261

0.999

25/75

Prostate

9.056×10-9

-7.186×10-6

2.232×10-3

0.708

-4.388

1

25/75

Rectum

2.222×10-8

-1.713×10-5

5.017×10-3

0.321

-4.402

0.999

25/75

Bladder

1.418×10-8

-1.714×10-5

3.868×10-3

0.494

-5.209

0.999

25/75

NT

7.586×10-9

-6.170×10-6

2.567×10-3

0.744

-4.682

1

Discussion:

For specific total dose values, a variance in BED values was seen. This is due to
BED being a function of individual isotope dose contributions and not the total dose.
Since a number of possible combinations exist to give rise to a specific total dose, this
was to be expected. However, the variance in BED was seen to be small. (The variance
in BED value was seen to be ~2 Gy when BED is 100 Gy, an error of 2%.) The

36

explanation for this is that not all possible combinations of isotope dose contributions that
add up to a specific total dose will be exist in the total isodose lines. Since multiple
sources were used and the isotopes within each source lie within the same voxel, dose
combinations along the same isodose line will vary although not all combinations will
occur.
This fast conversion of total dose to BED for low total dose values is not as
accurate as it for high dose values. The variance in BED values for total dose values
around 30 Gy is roughly the same as in higher total dose values (~2 Gy). This results in
an uncertainty of ~7%. Therefore, the uncertainty for low BED values when compared to
large BED is bigger (even though the variance was seen to be the same). The uncertainty
falls at larger total dose values since the variance remains the same.
Conclusions:

The work presented in this paper provides a fast calculation method of converting
total dose to BED for 50/50, 75/25 and 25/75 isotope ratios within hybrid seeds. These
conversions are calculated for specific organs: bladder, normal tissue, prostate and
rectum. In providing a fast calculation method, the need for solving a series of
transcendental equations was bypassed. This allows for BED based optimization of
treatment plans using these novel brachytherapy sources.
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Appendices

The following code is intended to be written as a generic version of the code used
within the scope of this study. There will be individual differences in details if this code
is to be implemented for in other similar studies.
The code was written using Mathematica 7. Descriptions of how the built in
functions within Mathematica work will not be described; however, descriptions of how
the functions are used. After each section, there will be a list of the definitions used
within the purpose of that section. Following this, a separation bar of “*” will occur to
denote the separation of definitions from code. A description of how the code works will
be displayed as necessary.
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Appendix A: Importing Files & Scaling Factor

PROSTATE: Prostate contour information; PROSTATE when defined has positional
values of either 0 or 255
RECTUM: Rectum contour information; RECTUM when defined has positional
values of either 0 or 255
BLADDER: Bladder contour information; BLADDER when defined has positional
values of either 0 or 255
I125DOSE: dose distribution information
scalingfactor: factor multiplying the I125DOSE so that the prostate dose coverage is 145
Gy
PixelCoordinateRow: Seed position information stored as a 1d list
ProstateDose: selected portion of I125DOSE that coincides with the PROSTATE. When
defined, the positional values will either be 0 or the values obtained from
I125DOSE
SingleDoseValuesForProstate: culled version of Prostate dose; the values within this
definition are only that obtained from I125DOSE
************************************************************************
SetDirectory["Wherever the information is located "];
PROSTATE = Import["PatientNameProstateContour.raw", "Data Format"];
RECTUM = Import["PatientNameRectumContour", "Data Format"];
BLADDER = Import["PatientNameBladderContour","Data Format"];
I125DOSE = scalingfactor*Import["PatientName_I125_Dose_Information","Data
Format"];
PixelCoordinatesRow = Import["PatientNamePixelCoordinatesRow","Data Format"]
The purpose of the scaling factor is to make sure that the dose distribution
imported meets the prescription requirements. The prescription requirement for the I125
reference plan is that the prostate volume receive a 145 Gy over 90% of the volume. This
scaling factor is the multiplied within the definition or I125DOSE (as already indicated).
ProstateDose = Table[
If[
PROSTATE[[x]]= =0, 0, I125DOSE[[x]]
],
{x,1, number of pixels within I125DOSE}];
SingleDoseValuesForProstate=Select[ProstateDose,#>0&];
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Appendix A (continued)

N[
Length[
Select[
potential_scaling_factor*SingleDoseValuesForProstate,#>145&
]
]
/Length[SingleDoseValuesForProstate]]
When the potential_scaling_factor is 1, the output of the previous line will also be 1. The
potential_scaling_factor is manually adjusted until the output of the previous line is .9.
The value of the potential scaling factor is now the value of the scaling factor.
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Appendix B: Geometry Portion Calculation

This part is intended to calculate the geometrical portions of the dose equation
(Equation [11]) separately from the rest of the equation. Aside from the geometrical part,
everything else can be reduce to a 1d list calculation (this reduces the calculation time
considerably)
I125RadialDoseFunctionDATA: Radial Dose Function (RDF) Data for I125; The RDF
data was given by the manufacturer in this study
RDF[r]: radial dose function for I125. Generated as a fit to
I125RadialDoseFunctionDATA. A function of distance, r
I125ΦDATA: Anisotropy function data for I125. The anisotropy function data was given
by the manufacturer in this study
Φ[r]: anisotropy function fitted to I125DATA
pl_: pixel to length conversion factor for dimension _ (either x, y, or z)
PD103RDFDATA: Radial Dose Function (RDF) Data for Pd103; The RDF data was
given by the manufacturer in this study
rdf[r]: radial dose function for Pd103 Generated as a fit to PD103RDFDATA. A
function of distance, r
PD103φDATA: Anisotropy function data for Pd103. The anisotropy function data was
given by the manufacturer in this study
φ[r]: anisotropy function fitted to PD103φDATA
g: number of seeds for the case being analyzed for
p: list of seed positions
c: local variable specifying the position of the seeds
GeometrySeedsRDFΦ[r]: Equation that calculates the geometrical portion for the 125I
BED distribution
GeometrySeedsrdfφ[r]: Equation that calculates the geometrical portion for the 103Pd
BED distribution
RDFMap: geometry function distribution for 125I
rdfMappd: geometry function distribution for 103Pd
************************************************************************
Since geometrical considerations are required for this study, generation of the
Radial Dose Functions and Anisotropy Functions are needed. Data for these functions
are given as a function of distance by the manufacturer. A linear fit is conducted for this
data for the respective functions. The functions are then coupled together within a
function.
One should note that generally the data given for the anisotropy and radial dose
functions are given in terms of length. The importing of dose distributions and
subsequent distributions will be in terms of discrete points or pixels. Appropriate pixel to
length conversion factors are needed for the respective dimensions. These parameters are
not listed here since this may or may not be the case generally; however, this information
can be added by simply multiplying each dimensional variable (x, y, z) within the
anisotropy and radial dose functions by an appropriate pl_.
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Appendix B (continued)

I125RadialDoseFunctionDATA={List};
RDF[r_]:=Fit[
I125RadialDoseFunctionDATA, {1,r},r
]
I125ΦDATA={List};
Φ[r_]:=Fit[

I125ΦDATA, {1,r},r
]
Since the geometry dependence is 3 dimensional, we need to account for this in our
variable.
Let r = √((With[{c=p, c[[n, 3]]]-x)2 + (With[{c = p, c[[n, 2]]]-y)2 +
(With[{c=p, c[[n, 1]]]- z)2)
RDFΦ[z_,y_,x_]:=RDF[z,y,x]* Φ [z,y,x]
PD103RDFDATA={List};
rdf[r_]:=Fit[
PD103RDFDATA, {1,r},r
]
PD103φDATA={List of data};
φ[r_]:=Fit[

PD103φDATA, {1,r},r
]
Again, since the geometry dependence is 3 dimensional, we need to account for this in
our variable.
Let r = √((With[{c=p, c[[n, 3]]]-x)2+(With[{c=p, c[[n, 2]]]-y)2+(With[{c=p, c[[n, 1]]]z)2)
rdfφ[z_,y_,x_]:=rdf[z,y,x]*φ[z,y,x]
p = {List of seed positions in 3 dimensions}
g = Length[p];
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Appendix B (continued)

RadiusSquared[z_, y_, x_]:= (x2+y2+z2)
GeometrySeedsRDFΦ[z_,y_,x_]:= If[
FreeQ[p, {z, y, x}]== True,
Sum[RDFΦ[z, y, x]/RadiusSquared[z, y, x],
{n, 1, g}], 0
]
GeometrySeedsrdfφ[z_,y_,x_]:= If[
FreeQ[p, {z, y, x}]== True,
Sum[rdfφ[z, y, x]/RadiusSquared[z, y, x],
{n, 1, g}], 0
]
RDFMap=Table[
GeometrySeedsRDFΦ[z,y,x],
{z, 1, number of slices}, {y, 1, number of pixels in y direction},
{x, 1, number of pixels in x direction}
]
rdfMappd=Table[
GeometrySeedsrdfφ[z,y,x],
{z, 1, number of slices}, {y, 1, number of pixels in y direction},
{x, 1, number of pixels in x direction}
]
d = Flatten[RDFMap];
z = Flatten[rdfMappd];
Export[“RDFMap”, d, “Data Format”]
Export[“rdfMappd”, z, “Data Format”]
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Appendix C: BED Calculation
∆: initial dose rate for 125I
δ: initial dose rate for 103Pd
I125DOSE: dose distribution for 125I
TH125: halflife for 125I
RECTUM: Rectum voxel positions
PROSTATE: Prostate voxel positions
BLADDER: Bladder voxel positions
α: coefficient for DNA damage proportional to dose
β: coefficient for DNA damage proportional to dose2
µ: repair constant
λ125: 125I decay constant
λPd: 103Pd decay constant
TP: Tumor Potential doubling time
TR__ = Tissue Repair constant; i.e. (NT = normal tissue):
PixelDesignation: Tells the code which biological parameters to use
d: local variable used to temporarily store the Teff distribution.
t: variable to temporarily store the Teff distribution
Teffective-single-allslice: Teff distribution file for 125I
BEDSingle-allslices: BED distribution for 125I
BEDSSPD: BED value of the selected voxel
Equations: set of equations used to solve for the initial dose rates and Teff
EffectiveTreatmentTimeSS: Teff for the selected voxel for 103Pd
PD103InitialDoseRateSS: δ for the selected voxel for 103Pd
TotalDosePD103SS: 103Pd dose distribution
PDTDMSS: 103Pd dose distribution but with seed positions taken into account; dose
values at seed position taken defaulted to 2000
skPDss: air kerma strength for each seed for 103Pd
Teffective-singlePD-allslice: Teff distribution file for 103Pd
BEDSingle-allslicesPd: BED distribution for 103Pd
PD103InitialDoseRate: δ for the selected voxel for hybrid seed
EffectiveTreatmentTime: Teff for the selected voxel for hybrid seed
I125InitialDoseRate: ∆ for the selected voxel for hybrid seed
SK: air kerma strength for 125I portion of the hybrid seed
sk: air kerma strength for 103Pd portion of the hybrid seed
SKI125: value of the air kerma strength for 125I portion of the hybrid seed for a specified
position
TotalDoseI125: 125I dose portion for the hybrid dose distribution
I125TDM: 125I dose portion for the hybrid dose distribution with seed positions
skPD: value of the air kerma strength for 103Pd portion of the hybrid seed for a specified
position
TotalDosePD103: 103Pd dose portion for the hybrid dose distribution
PDTDM: 103Pd dose portion for the hybrid dose distribution with seed positions
TD: dose distribution for hybrid seed
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Appendix C (continued)

Teffective-mixed-allslice: Teff distribution file for hybrid seeds
BEDHYBRID-allslices: BED distribution for hybrid seeds
************************************************************************
The first thing that needs to be done is to convert the dose distribution file to an
initial dose rate distribution file since the BED calculation uses initial dose rates. The
BED calculation also requires to know the Teff distribution. Therefore, calculation of Teff
prior to the BED calculation is needed.
For 125I BED Calculation:
∆ = Table[
If[

I125DOSE[[x]]<0, 0, I125DOSE[[x]]/(1.44*TH125)
],
{x,1, number of pixels in dose distribution}
];
PixelDesignation[x_]:=
If[ (RECTUM[[x]] + PROSTATE[[x]] + BLADDER[[x]]) = = 0,
α =.20; β = α /3.00; µ = Log[2]/TRNT,
If[ (RECTUM[[x]] + BLADDER[[x]]) = = 0,
α =.15; β= α /3.10; µ = Log[2]/TRPROSTATE,
If[ BLADDER[[x]] = = 0,
α =.0484; β = α /3.90; µ = Log[2]/TRRECTUM,
α =.0774; β = α /3.95, µ = Log[2]/TRBLADDER
]
]
];
d = Table[
If[ I125DOSE[[x]] <1, Q=0,
PixelDesignation[x];
Q=t/.
FindRoot[∆[[x]] e-λ125*t+2(β/α) ∆[[x]]2/(µ- λ125)(e-2/λ125*t-e-(µ + λ125)t)
-0.693/(α × TP),
{t,50}]
],
{x, 1, number of pixels in dose distribution}];
Export["Teffective-single-allslice", d, "Data Format"]
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Appendix C (continued)

t = Import["Teffective-single-allslice", " Data Format"];
d = Table[
If[ I125DOSE[[x]] <1, Q=0,
PixelDesignation[x];
∆[[x]]/ λ125 (1-e-λ125*t[[x]]) + 2(β/α) ∆2/(µ - λ125)*
*(1/(2* λ125)(1- e-2 λ125*t[[x]]) - 1/(µ + λ125) (1-e-(µ + λ125)t[[x]]))
- (.693* t[[x]])/(α *TP)
],
{x, 1, number of pixels in dose distribution }];
Export["BEDSingle-allslices", d, "Data Format"]
For 103Pd BED Calculation
The BED distribution for 125I plans has now been calculated. As verification of
the method, a prescription dose will be calculated for 103Pd. First, a pixel must be
selected to provide a value for the BED. From this, the initial dose rate and Teff can be
calculated. After which, the activity of the each seed can be calculated allowing for the
initial dose rate distribution to be calculated.
BEDSingleallslices = Import["BEDSingle-allslices", "Data Format"];
BEDSSPD = BEDSingleallslices[[pixel position of selected voxel]]
The method for deriving the BED distribution is exactly the same for 103Pd as for
50/50 hybrid seeds. The only difference is the set of equations that are used to solve for
initial dose rates and Teff.
Equations[t_,δ_]:={
δe- λPd *t+2(β/α) δ2/(µ- λPd)(e-2/λPd*t-e-(µ + λPd)t)-0.693/(α × TP)==0,
0 == δ/ λPd (1-e-λPd* t) + 2(β/α) δ2/(µ - λPd)*
*(1/(2*λPd)(1- e-2 λPd * t) - 1/(µ + λPd)(1-e^-(µ + λPd)t))
- (.693* t)/(α *TP) - BEDSSPD
}
Block[{x = pixel position of selected voxel, α =.15, β = α /3.10, µ =
Log[2]/TRPROSTATE},
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Appendix C (continued)

d = {Q, L} = {t, δ}/.
FindRoot[
Equations[t, δ], {{t, initial guess, min of range, max of range},
{δ, initial guess, min of range, max of range}}]
];
w = {Part[d,1],Part[d,2]};
{
EffectiveTreatmentTimeSS = Part[w,1],
PD103InitialDoseRateSS=Part[w,2]
}
With the initial dose rate and Teff for 103Pd for the selected voxel calculated, the air kerma
strength needs to be calculated for each seed.
skPDss[z_,y_,x_]:=
PD103InitialDoseRateSS/Sum[drc*(rdfφ[z, y, x]/RadiusSquared[z, y, x]),
{n, 1, g}];
Take note, when actually calculating skss, the voxel position must be translated to
3d coordinates. With activity calculated, dose distribution can be calculated.
TotalDosePD103SS=1.44*THPD*drc*skPDss*Import["rdfMappd","Real32"];
PDTDMSS = Table[
If[PixelCoordinatesRow[[x]] == 1, 2000, Q = TotalDosePD103SS[[x]];
If[Q<=0,0,Q]],
{x, 1, number of pixels in dose distribution}];
125

After the dose distribution is calculated, the remaining steps are the same as in the
I BED calculation but parameters are appropriately changed.

δ = Table[
If[

PDTDMSS[[x]]<0, 0, PDTDMSS[[x]]/(1.44*THPD)
],
{x, 1, number of pixels in dose distribution }];
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Appendix C (continued)

d = Table[
If[I125DOSE[[x]] <1, Q=0,
PixelDesignation[[x]];
Q=t/.
FindRoot[δ[[x]]e-λPd* t + 2(β/α)(δ[[x]]2/(µ- λPd))(e-2/λPd*t-e-(µ + λPd)t) - 0.693/(α ×
TP),
{t,50}]
],
{x, 1, number of pixels in dose distribution}];
Export["Teffective-singlePD-allslice ", d, "Data Format"]
t = Import["Teffective-singlePD-allslice", " Data Format"];
d = Table[
If[ I125DOSE[[x]] <1, Q=0,
PixelDesignation[x];
(δ/ λPd) (1-e-λPd* t) + 2(β/α)((δ2/(µ - λPd))(1/(2*λPd))(1- e-2 λPd* t) – (1/(µ +
λPd))(1-e^-(µ + λPd)t)) - (.693* t)/(α *TP)
],
{x, 1, number of pixels in dose distribution }];
Export["BEDSingle-allslicesPd", d, "Data Format"]
For 50/50 Hybrid Seed BED Calculation
Since there are 3 unknowns, t, δ, and ∆, there is a need to rewrite the Equations
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Equations[t_, δ_, ∆_]:= {
0 == δ*e-t* λPd + ∆*e-t* λ125 +

(

2(β/α)
((δ2/(µ - λPd))(e-2/λPd*t - e-(µ + λPd)t) + (∆2/(µ - λ125)) (e-2 λ125*t - e-(µ + λ125)t)) +
((δ*∆)/(µ - λPd)) (e-t*(λPd + λ125) - e-t*(µ + λ125))
+ ((δ*∆)/(µ - λ125)) (e-t*(λPd + λ125) - e-t*(µ + λPd))

) - .693/(TP * α),
0 == (δ/λPd)(1- e-λPd* t) + (∆/ λ125)(1- e-λ125*t) +

(

2(β/α)
((δ2/(µ - λPd))((1/(2*λPd))(1- e-λPd* t) – (1/(µ + λPd))(1- e^-(µ + λPd)t))) +
((∆2/(µ - λ125))((1/(2*λ125)) (1- e-2 λ125*t)-1/(µ + λ125) (1- e-t*(µ + λ125)))) +
((δ*∆)/(µ - λPd))((1/(λPd + λ125)) (1 - e-t*(λPd + λ125)) –
(1/( µ + λ125)) (1- e-t*(µ + λ125)))
+
((δ*∆)/(µ - λ125))((1/(λPd + λ125)) (1 - e-t*(λPd + λ125)) - (1/(µ + λPd)) (1e^-(µ + λPd)t))

) - (.693*t)/(TP*α) - BEDSSPD
∆/δ ==

(.22*DRC*Sum[RDFΦ[z, y, x]/RadiusSquared[z, y, x],{n,1,g}])
/
(1.42*drc*Sum[rdfφ[z, y, x]/RadiusSquared[z, y, x],{n,1,g}]),
}
Similar steps are taken as in calculation for 103Pd. First the initial dose rates need
to be calculated first so that the air kerma strength of each seed can then be determined.
With the air kerma strengths known, dose and BED distributions can be calculated.
Please note the calculations for the initial dose rates and Teff are in three dimensions, so
the Equations and PixelDesignation should change appropriately.
Block[{{z, y, x} = pixel position of selected voxel, α =.15, β = α /3.10,
µ = Log[2]/TRPROSTATE},
d = {Q, L, M} = {t, δ, ∆}/.
FindRoot[
Equations[t, δ, ∆], {{t, initial guess, min of range, max of range},
{δ, initial guess, min of range, max of range}, {∆, initial guess,
min of range, max of range}}]
];
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w = {Part[d,1],Part[d,2], Part[d,3]};
{
EffectiveTreatmentTime = Part[w,1],
PD103InitialDoseRate = Part[w,2],
I125InitialDoseRate = Part[w,3]
}
Dose distributions can be calculated from the determined initial dose rates.
SK[z_,y_,x_]:=
I125InitialDoseRate
/
Sum[DRC RDFΦ[z, y, x]/RadiusSquared[z, y, x],{n,1,g}];
sk[z_,y_,x_]:=
PD103InitialDoseRate
/
Sum[drc rdfφ[z, y, x]/RadiusSquared[z, y, x],{n,1,g}];
TotalDoseI125 = 1.44*TH125*DRC*SKI125*Import["RDFMap","Real32"];
I125TDM = Table[
If[

PixelCoordinatesRow[[x]] == 1,2000,
Q = TotalDoseI125[[x]];
If[Q<=0, 0, Q]

],
{x,1, number of pixels in dose distribution }];
Export["I125TDM", I125TDM, "Data Format"];
TotalDosePD103 = 1.44*THPD*drc*skPD*Import["rdfMappd","Real32"];
PDTDM = Table[
If[

PixelCoordinatesRow[[x]]==1,2000,
Q=TotalDosePD103[[x]];
If[Q<=0,0,Q]

],
{x,1, number of pixels in dose distribution }];
Export["PDTDM", PDTDM, " Data Format "]
TD = PDTD + I125TD;
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Export["TD", TD, "Real32"];
With the total dose distribution calculated, BED distribution calculation
follows the same steps as in the previous calculations.
δ = PDTD/(1.44*THPD);
∆ = I125TD/(1.44*TH125);

d = Table[
If[(δ[[x]]+ ∆[[x]])==0,
Q=0,
PixelDesignation[[x]];
Re[Q=t/.
FindRoot[δ*e-t* λPd + ∆*e-t* λ125 +

(

2(β/α)
((δ[[x]]2/(µ - λPd))(e-2/λPd*t - e-(µ + λPd)t) +
+ (∆[[x]]2/(µ - λ125))(e-2 λ125*t - e-(µ + λ125)t))
+ ((δ[[x]]*∆ [[x]])/(µ - λPd)) (e-t*(λPd + λ125) - e-t*(µ + λ125))
+ ((δ[[x]]*∆[[x]])/(µ - λ125)) (e-t*(λPd + λ125) - e-t*(µ + λPd))

) - .693/(TP * α),{t,100}
]
]
];
If[Q>0&&Q!= 100., Q, Q=0],
{x, 1, number of pixels in dose distribution }];
Export["Teffective-mixed-allslice", d, " Data Format"]];
t = Import["Teffective-mixed-allslice", "Data Format"];
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Appendix C (continued)

d = Table[
If[(δ[[x]] + ∆[[x]])==0,
Q=0,
PixelDesignation[[x]];
(δ[[x]]/λPd)(1- e-λPd* t) + (∆[[x]]/ λ125)(1- e-λ125*t) +
2(β/α)

(

((δ[[x]]2/(µ - λPd))((1/(2*λPd))(1- e-λPd* t) – (1/(µ + λPd))(1- e^-(µ + λPd)t)))
+ ((∆[[x]]2/(µ - λ125))((1/(2*λ125)) (1- e-2 λ125*t)-1/(µ + λ125) (1- e-t*(µ + λ125))))
+ ((δ[[x]]*∆[[x]])/(µ - λPd))

(

(1/(λPd + λ125)) (1 - e-t*(λPd + λ125)) – (1/( µ + λ125)) (1- e-t*(µ + λ125))

)

+ ((δ[[x]]*∆[[x]])/(µ - λ125))

(

(1/(λPd + λ125)) (1 - e-t*(λPd + λ125)) - (1/(µ + λPd)) (1- e^-(µ + λPd)t)

)

) - (.693*t)/(TP*α)
],
{x, 1, number of pixels in dose distribution}];
Export["BEDHYBRID-allslices", d, "Data Format"]
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